Feedback PLC Attendance at European Congress of Radiology
27 Februar 2015 - 8:02AM
RNS Non-Regulatory
TIDMFDBK
Feedback PLC
27 February 2015
27 February 2015
Feedback plc
("Feedback", the "Company" or the "Group")
Attendance at European Congress of Radiology
Feedback plc will be attending the European Congress of
Radiology ("ECR") - the scientific assembly and annual meeting of
the European Society of Radiology from 4th March to 8th March 2015
at the Austria Center in Vienna, Austria. Dr. Balaji Ganeshan,
Chief scientist & New Business Officer, TexRAD Limited &
Cambridge Computed Imaging Limited ("CCI") and other collaborators
will be presenting a number of TexRAD related papers particularly
in breast (novel quantitative radiomic analysis to identify
high-risk breast cancer phenotype on PET-CT), colorectal
(pre-operative CT texture analysis predicts outcome in patients
with colorectal liver metastases post liver resection and MR
texture analysis was a better marker of response to Neoadjuvant
Chemotherapy in rectal cancer patients on 3-T MR than diffusion and
perfusion parameters) and lung (multi-parametric PET-CT correlates
with hypoxia, angiogenesis and ALK expression) cancers at ECR.
For further information contact:
Feedback plc Tel: 01954
718072
Simon Barrell/Trevor Brown/Tom
Charlton
Sanlam Securities UK (Nominated adviser)
Simon Clements / Virginia Bull Tel: 020 7628
2200
Notes to editors:
TexRAD (is a novel sophisticated imaging risk stratification
research tool that analyses the textures in existing radiological
scans. This research software application analyses textures,
detecting and measuring tumour heterogeneity (complexity) from
these images, revealing more information from medical images than
it is currently possible to see with the naked eye. Research to
date has shown that TexRAD could potentially assist the clinician
(as an 'Imaging-Biomarker') in confident decision-making: assessing
the prognosis, disease-severity (e.g. risk of metastases) and
response evaluation of patients with cancer. Currently TexRAD
research has shown great potential in many different oncological
sites, including, colorectal, breast, lung, prostate, oesophageal,
head & neck, lymphoma, liver and renal cancers and could
potentially be employed as a heterogeneity assessing tool in the
era of 'Precision and Personalized Medicine'.TexRAD is manufactured
under licence by the ISO 13485 certified company Cambridge Computed
Imaging Ltd, a subsidiary of Feedback plc. More information is
available on www.fbk.com and www.texrad.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABIGDDBBDBGUL
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024